Author:
De la Parra Irene,Gómez Rivas Juan,Gutiérrez Beatriz,Marugán María Jesús,Enikeev Dmitry,Somani Bhaskar K.,Barrera Jerónimo,Moreno-Sierra Jesús
Abstract
Since overdiagnosis and overtreatment pose significant risks in managing prostate cancer (PCa), active surveillance (AS) is the most common treatment in low-risk patients. However, there is no general agreement yet on the inclusion criteria and the required follow-up. Multiparametric magnetic resonance imaging (mpMRI) of the prostate was born as a useful device in these patients both in diagnosis and follow-up, and it is widely used in daily clinical practice. We reflect on the most current evidence described in the literature on the topic, its results, and our experience.
Reference71 articles.
1. FRCSC. Active surveillance of prostate cancer;Klotz L,2021
2. The emerging role of MRI in prostate cancer active surveillance and ongoing challenges;Barrett;AJR Am J Roentgenol,2017
3. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent;Mottet,2021
4. NCCN guidelines insights: prostate cancer, version 1.2021;Schaeffer;J Natl Compr Canc Netw,2021
5. Prospective validation of active surveillance in rostate cancer: the PRIAS study;Van den Bergh;Eur Urol,2007